Cream 0.1% w/w
Each preparation contains mometasone furoate (Micronised) 1 mg/g.
A white to off white, smooth homogenous mass
Mometasone furoate has anti-inflammatory and anti-psoriatic activity.
Systemic absorption following topical application of mometasone furoate 0.1
% is minimal (approximately 0.4% of the applied dose), the majority of which
is excreted within 72 hours following application.
Relief of the inflammatory and pruritic manifestation of
corticosteroid-responsive dermatoses such as psoriasis and atopic
A thin film of Metasone Cream 0.1 % should be applied to the affected skin
areas once daily until the lesion heals or for a duration of 3 weeks
whichever is sooner.
Contraindicated in facial rosacea, acne vulgaris, perioral dermatitis,
perianal and genital pruritis, napkin eruption, bacterial (e.g. impetigo),
viral (e.g. herpes simplex, herpes zoster and chickenpox) and fungal (e.g.
candida or dermatophyte) infections, varicella, tuberculosis, syphilis or
post-vaccine reactions. Metasone should not be used in patients who are
sensitive to mometasone furoate or to other corticosteroids.
Warning and precaution:
If irritation or sensitisation develops with the use of Metasone, treatment
should be withdrawn and appropriate therapy instituted. An appropriate
antifungal or antibacterial agent should be instituted if an infection
develops. If a favourable response does not occur promptly, the
corticosteroid should be discontinued until the infection is adequately
controlled. Any of the side effects that have been reported following
systemic use of corticosteroids, including adrenal suppression, may also
occur with topical corticosteroids, especially in infants and children.
Systemic absorption of topical corticosteroids will be increased if
extensive body surface areas are treated or if the occlusive technique is
used. Metasone is not for ophthalmic use.
Pregnancy and lactation:
There is inadequate evidence of safety in human pregnancy. Topical
administration of corticosteroids to pregnant animals can cause
abnormalities of foetal development including cleft palate and intra-uterine
growth retardation. Topical corticosteroids should be used during pregnancy
only if the potential benefit justifies potential risk to the fetus. Drugs
of this class should not be used on pregnant patients in large amounts or
for prolonged periods of time. It is not known whether topical
administration of corticosteroids could result in sufficient systemic
absorption to produce detectable quantities in breast milk. Metasone should
be administered to nursing mothers only after careful consideration of the
Local adverse reactions rarely reported include burning, folliculitis,
acneiform reaction, pruritus, paresthesia, tingling/stinging, and signs of
The following local adverse reactions have been reported infrequently with
the use of other topical corticosteroids: Irritation, hypertrichosis,
hypopigmentation, perioral dermatitis, allergic contact dermatitis,
maceration of the skin, secondary infections, striae and miliaria.
Store in a dry place below 30°C.
For external use only.
Keep out of reach of children.
Shelf life: 3 years
Aluminium tubes of 5g, 10g and 15g